Further research is required to investigate the consequences of this approach towards prostate cancer risk, although our findings using genetic proxies of PCSK9 inhibition predict that this would have a beneficial effect, especially on early-onset prostate cancer. This evidence concerns the gene PCSK9 and Familial prostate cancer.